Menu
PGx testing can help you and your doctor identify which medications are most effective for you, at what dose, and how long you should take them. Knowing this information can help avoid the trial-and-error approach of trying different medications until one works while minimizing the risk of side effects. By identifying which medications are most effective, you can improve your treatment outcomes, feel better, and manage any health conditions more effectively. Precisely the benefits include:
PGx testing helps identify the most effective medications and doses that are tailored to a patient’s unique genetic makeup.
PGx testing helps identify specific medications that may cause harmful reactions, reducing these risks for patients.
Identifying the most suitable drugs for a patient can increase their response to treatment and improve their health outcomes.
PGx testing helps ensure that patients receive safe and effective treatments tailored specifically to their genetic makeup.
PGx testing leads to quicker identification of the optimal treatments, which saves time and resources.
Personalized treatments help to reduce waste and prevent adverse reactions, lowering treatment costs in the long-term.
Personalized treatment plans can lead to improved health outcomes for patients, which often results in increased satisfaction and adherence to the treatment plan.
Not all antidepressants work in the same way for every individual. These medicines can trigger side effects, such as dizziness, nausea, and weight gain, that negatively impact treatment adherence. PGx testing utilizes a person’s genetic profile to detect potential side effects. By avoiding medications that are likely to produce such side effects, patients can increase their chances of adhering to the appropriate medication plan.
PGx testing can assist doctors in prescribing the most suitable chemotherapy treatment plan and dosage that will maximize therapeutic benefits while minimizing side effects. It can also help in identifying patients who are at a higher risk of chemotherapy-induced toxicity, thereby enabling medical professionals to devise a comprehensive risk management plan.
PGx helps in optimizing blood thinners medication, such as warfarin, by providing individualized treatment plans for patients based on their genetic makeup. It helps doctors to modulate the medication doses to achieve optimal therapeutic benefits while minimizing the risk of negative side effects and adverse reactions. This approach can significantly reduce the risk of related complications such as bleeding and clotting adverse events.
It helps in identifying how a patient responds to specific pain management drugs, including opioids. It can reduce the risk of under or over-medication, decrease the likelihood of adverse side effects, and avoid medication interactions with other medications that the patient might be taking.
PGx testing enhances the recruitment process by enabling the selection of participants who are more likely to respond positively to the medication being tested, resulting in a more targeted and efficient approach. Furthermore, by categorizing patients according to their genetic makeup, the variability in drug response is minimized, leading to more reliable and consistent trial outcomes.
Understanding a participant’s genetic profile allows for more precisely tailored interventions, which increases the likelihood of achieving desired therapeutic outcomes and enhances the chances of demonstrating significant efficacy in trials, as treatments are tested on participants genetically predisposed to respond favorably.
PGx testing can identify participants at higher risk for adverse drug reactions (ADRs) before they occur, allowing for proactive management and improved patient safety, thereby supporting the ethical obligation to ensure the safety of trial participants and reinforcing responsible conduct in clinical trials.
By selecting the right participants from the start, clinical trials can be conducted more efficiently, potentially reducing overall costs and the duration of the study. This streamlined approach leads to clearer and more positive trial outcomes, which can expedite regulatory approvals for new treatments.
PGx data can support submissions to regulatory agencies by providing detailed evidence of a drug’s efficacy and safety across different genetic profiles, and continued monitoring of genetic markers in post-market studies can offer insights into long-term efficacy and safety, further satisfying regulatory requirements.
Participants experiencing better health outcomes are more likely to remain in the study and comply with trial protocols, as safer and more effective treatment responses contribute to a positive experience that enhances retention rates.
